Benitec Biopharma Inc. (BNTC) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Benitec Biopharma Inc. (BNTC) closed at USD 8.29 on 2026-10-14, a change of -48.7 % over the past year, with a market capitalization of USD 295.11M.

Benitec Biopharma Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Benitec Biopharma Inc. key figures

Previous close

USD 8.29 (2026-10-14)

1-year change

-48.7 %

Market cap

USD 295.11M

Enterprise value

USD 115.9M

P/E ratio (trailing)

-8.81

P/E ratio (forward)

-0.90

EPS (trailing)

-0.96

EPS (forward)

-9.42

PEG ratio

n/a

Price to book

1.64

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

13.26

Employees

24

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Benitec Biopharma Inc.

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene, which is in phase 1b/2a for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Benitec Biopharma Inc. and compare it with other stocks.